15 completed, 4 recruiting, 3 active not recruiting, 3 terminated. 30 Phase 2, 8 Phase 1, 4 Phase 3.
Follow Granuloma: new trials by email Literature Review of Granuloma trials Research Report on Granuloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The GranStone Trial empagliflozin (Jardiance) 25 mg, Losartan 100 mg - Paraffinoma, Granuloma, Foreign-Body | Phase 2 / Phase 3 | Recruiting | Martin Blomberg Jensen | 100 | 2026-10-20 | 2026-11-10 |
| Tyrosine Kinase 2 (TYK2) for GA and CS Deucravacitinib - Sarcoidosis, Granuloma Annulare | Phase 2 | Withdrawn | Yale University | 2025-03-01 | 2025-04-29 | |
| Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis Tezepelumab, Placebo - EGPA - Eosinophilic Granulomatosis With Polyangiitis | Phase 2 | Active not recruiting | Imperial College London | 42 | 2024-05-15 | 2026-04-29 |
| Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis NS-229, Placebo - Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome | Phase 2 | Active not recruiting | NS Pharma, Inc. | 45 | 2023-12-20 | 2026-05-26 |
| A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA） SHR-1703, Mepolizumab Injection - Eosinophilic Granulomatosis With Polyangiitis | Phase 2 / Phase 3 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 166 | 2023-11-16 | 2025-12-04 |
| Janus Kinase Inhibition in Granuloma Annulare Abrocitinib 200 mg - Granuloma Annulare | Phase 2 | Completed | William Damsky | 10 | 2023-10-27 | 2026-10-07 |
| An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases Povetacicept - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Active not recruiting | Alpine Immune Sciences, Inc. | 72 | 2023-03-15 | 2026-10-20 |
| Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors Brigatinib - Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor | Phase 1 / Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 65 | 2022-08-18 | 2025-12-05 |
| The Efficacy of Laser in Root Canal Disinfection Conventional group (NaOCl/EDTA), Dual laser group (Er,Cr:YSGG/Diode):, Combined group (EDTA/Diode): - Pulp and Periapical Tissue Disease, Pulp Necroses | Phase 2 | Completed | Future University in Egypt | 30 | 2022-01-01 | 2023-11-29 |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Oral repotrectinib (TPX-0005) - Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Turning Point Therapeutics, Inc. | 75 | 2020-03-12 | 2026-09-25 |
| Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Naltrexone Hydrochloride, Placebo Comparator - Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS) | Phase 2 | Completed | University of Pennsylvania | 60 | 2019-02-04 | 2026-01-22 |
| Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors Crizotinib - Inflammatory Myofibroblastic Tumor | Phase 2 / Phase 3 | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 25 | 2019-02-01 | 2019-03-14 |
| Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis Efzofitimod 1.0 mg/kg or Placebo, Efzofitimod 3.0 mg/kg or Placebo, Efzofitimod 5.0 mg/kg or Placebo - Pulmonary Sarcoidosis | Phase 1 / Phase 2 | Completed | aTyr Pharma, Inc. | 37 | 2019-01-29 | 2023-07-18 |
| Denosumab in Subjects With Giant Cell Rich Tumors of Bone Denosumab - Aneurysmal Bone Cysts, Giant Cell Granuloma | Phase 2 | Unknown | Leiden University Medical Center | 60 | 2018-06-18 | 2019-08-26 |
| Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis ACZ885, Placebo - Pulmonary Sarcoidosis | Phase 2 | Completed | Novartis Pharmaceuticals | 40 | 2016-12-19 | 2021-10-04 |
| Ceritinib Rare Indications Study in ALK+ Tumors Ceritinib (LDK378) - Tumors With Aberrations in ALK, Anaplastic Large Cell Lymphoma | Phase 2 | Terminated | Novartis Pharmaceuticals | 22 | 2016-05-06 | 2019-12-27 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| Efficacy Study of Botulinum Toxin (BOTOX) Injections to Treat Vocal Fold Granulomas onabotulinumtoxinA, omeprazole (proton pump inhibitor) - Contact Ulcer of Vocal Folds, Granuloma of Vocal Cords | Phase 2 | Withdrawn | Phillip Song, MD | 2012-09-01 | 2017-03-28 | |
| CREATE: Cross-tumoral Phase 2 With Crizotinib Crizotinib (PF-02341066) - Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 582 | 2012-09-01 | 2023-12-11 |
| Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Hematopoietic stem cell transplantation - Sickle Cell Disease, Thalassemia | Phase 1 / Phase 2 | Completed | Children's Hospital Los Angeles | 25 | 2008-08-01 | 2016-06-23 |
Showing 20 of 30. Sign in to see all of them.
Churg-Strauss Syndrome (11) · Granuloma, Plasma Cell (6) · Granulomatosis with Polyangiitis (5) · Lymphoma, Large-Cell, Anaplastic (4) · Microscopic Polyangiitis (4) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Granuloma Annulare (3) · Sarcoidosis (3) · Vasculitis (3) · Glioblastoma (2) · Granuloma, Giant Cell (2) · Inflammation (2) · Lymphoma (2) · Lymphoproliferative Disorders (2)
Hemic and Lymphatic Diseases (23) · Lymphatic Diseases (23) · Immune System Diseases (21) · Lymphoproliferative Disorders (21) · Pathologic Processes (19) · Pathological Conditions, Signs and Symptoms (19) · Skin and Connective Tissue Diseases (17) · Skin Diseases (16) · Cardiovascular Diseases (13) · Vascular Diseases (13) · Autoimmune Diseases (12) · Skin Diseases, Vascular (12) · Systemic Vasculitis (12) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (9)
mepolizumab (4) · Crizotinib (2) · Cyclophosphamide (2) · Abatacept (1) · Botulinum Toxins, Type A (1) · Capsules (1) · Denosumab (1) · Doxorubicin (1) · Hematopoietic Stem Cell Transplantation (1) · Ifosfamide (1) · Losartan (1) · Methotrexate (1) · Naltrexone (1) · Omeprazole (1) · Prednisone (1)
Imperial College London (2) · Novartis Pharmaceuticals (2) · Alpine Immune Sciences, Inc. (1) · Brigham and Women's Hospital (1) · Children's Hospital Los Angeles (1) · Children's Hospital Medical Center, Cincinnati (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Fernando Fervenza (1) · Future University in Egypt (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Leiden University Medical Center (1) · Martin Blomberg Jensen (1) · NS Pharma, Inc. (1) · National Cancer Institute (NCI) (1)
United States (17) · France (6) · Italy (6) · United Kingdom (5) · Canada (4) · Germany (4) · Netherlands (4) · Denmark (3) · South Korea (3) · Spain (3) · Australia (2) · Puerto Rico (2) · Belgium (1) · China (1) · Czechia (1)
AJ Gelderblom, Prof (1) · Aaron R Weiss (1) · Alan Salama (1) · Antonio T. Fojo, MD, PhD (1) · Carlo Buzio, MD (1) · Fernando C. Fervenza, M.D., Ph.D. (1) · Gennyne Walker (1) · Hisham Abdel-Azim, MD (1) · John J Voorhees, MD (1) · Marc E. Rothenberg, MD (1) · Martin B Jensen, Professor (1) · Michael Wechsler, MD (1) · Michel Zwaan, Prof (1) · Peter A Merkel, MD, MPH (1)
PMID 21325353, PMID 28950372, PMID 29016646, PMID 29216400, PMID 29567632, PMID 29669701, PMID 32702309, PMID 32827353, PMID 34392187, PMID 34515544, PMID 34814185, PMID 36356657, PMID 37449658, PMID 37523624, PMID 37854715
2023 (1), U10CA098543 (1), U10CA180830 (1), U10CA180886 (1), UL1RR024150 (1)